Teva Pharma To Present Data From Studies Of Azilect And Parkinson's Disease

(RTTNews.com) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that data from studies of Azilect (rasagiline tablets) and Parkinson's disease or PD will be presented at the 16th Annual International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland, 17-21 June 2012.

The company said the presentations include ongoing studies assessing effects of Azilect treatment on motor and non-motor PD symptoms, both as monotherapy and when added to ongoing dopamine agonist therapy.

Azilect tablets (rasagiline tablets) are indicated for the treatment of the signs and symptoms of Parkinson's disease both as initial therapy alone and to be added to levodopa later in the disease in patients with end-of-dose fluctuations.

The company noted that patients should not take Azilect if they are taking meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, cyclobenzaprine, or other monoamine oxidase inhibitors (MAOIs), as it could result in a serious reaction.

Side effects seen with Azilect alone are flu syndrome, joint pain, depression, and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesia), accidental injury, weight loss, low blood pressure when standing, vomiting, anorexia, joint pain, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Read the original here:
Teva Pharma To Present Data From Studies Of Azilect And Parkinson's Disease